PMGC starts preclinical study of muscle preservation therapy EL-32
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
NorthStrive Biosciences Announces Launch of EL-32 Preclinical Study Evaluating Muscle Preservation in GLP-1 Weight Loss Therapy
March 10, 2026 7:30 AM EDTNEWPORT BEACH, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (PMGC or the Company) today announced the initiation of a preclinical study for EL-32, an engineered probiotic candidate being developed by its wholly owned subsidiary, NorthStrive Biosciences Inc. (NorthStrive Biosciences). The study is designed to evaluate EL-32s potential to preserve lean muscle mass while promoting fat loss, both as a standalone therapy and in combination with GLP-1 weight loss treatments.
This announcement follows the Companys January 30, 2025 press release titled NorthStrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Signs Agreement for Preclinical... More
